Supportive Care in Cancer Treatment - Some first-generation products proving difficult to dislodge

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2006-10-09

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Supportive care is used to prevent or treat the adverse effects that arise as a result of cancer treatment, particularly chemotherapy. While newer molecular targeted therapies do not exist without some toxicity, this is not as severe as that associated with traditional cytotoxics. A rising incidence of cancer worldwide will mean that supportive care market will increase both size and relevance.


Scope

  • Treatment trends in the use of supportive care pharmacotherapy, including its association with major tumor types and therapy regimens
  • Analysis of brand preference within four supportive care pharmacotherapy drug classes based on a survey of 180 physicians across the seven markets
  • Physician awareness and use of various supportive care guidelines, including those from the NCCN, ASCO and EORTC
  • Ranking of the greatest areas of unmet need within the supportive care market and the likelihood of key future scenarios occurring


    • Report Highlights
    Approximately 7080% of all cancer patients who receive cytotoxics suffer nausea and/or vomiting, which has led to widespread acceptance of anti-emetic strategies as an integral component of chemotherapy treatment. In particular, the ubiquitous use of serotonin antagonists is evidenced by the number of products in this drug class.

    Incidence of cytopenias is dependent on the use of chemotherapy and the nature of the disease, with hematological malignancies requiring greater supportive care measures. The biologic nature of growth factors used in treatment has translated into high therapy costs, which has somewhat restricted their use in the EU and surprisingly, in the US.

    A major focus of current clinical research is the viability of bisphosphonates in the adjuvant setting, to prevent bone metastases prior to their formation. If trial results prove encouraging, a major commercial opportunity exists for those drug developers willing to become involved, particularly if one of the 'big four' tumor types is targeted.


    Reasons to Purchase

  • Identify key factors that influence prescribing patterns for supportive care pharmacotherapy
  • Examine the significant unmet needs in the supportive care market and identify opportunities for new product development
  • Enhance commercial positioning by increasing understanding of current dynamics within the supportive care market

    • Table of Contents

    Other users found this report page using the following search terms: supportive care cancer oncology antinauseants nausea vomiting antiemetics pain infection control neutropenia anemia bondronat price spain febrile neutropenia key opinion leaders granocyte erythropoiesis

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.